Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Equity Raises:
- There were no closed equity transactions this week.
Public vs. Private Raises:
- There were no closed capital raises this week
Equity vs. Debt Cap Raises:
- Debt accounted for 92% of trailing 8-week capital raises. The ratio may go down if companies are able to utilize favorable regulatory-induced stock price increases to complete equity issues. We believe that a successful move to S3 will increase the likelihood of other near-term regulatory moves, such as the SAFER or STATES. The real question is what kind of price increase will it take before cannabis companies are willing to issue equity? Will the change to S3 result in a lasting price pop that could lead to re-equitization?
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.